Quant Biomarkers established to develop sophisticated analytical products
Quant Biomarkers - 10-Dec-2021DKG subsidiary to introduce biomarker-driven Longevity risk mitigation and intervention support
Join the club for FREE to access the whole archive and other member benefits.
CEO Quant Biomarkers and Managing Partner Deep Knowledge Group
More than a decade of work as strategic development head for several large Swiss and international pharmaceutical corporations (Novartis, Abbott Life Sciences).
Dr. Tomovska has a vast amount of experience across pharmaceutical portfolio stages and business delivery: strategy, lifecycle, venture development, R&D, M&A, clinical, marketing, and change management. She holds a PhD in molecular biology from the University of Basel, Switzerland in Biomarkers in Cancer Diagnostics and has a business education from INSEAD and Columbia Business School.
Visit website: https://www.quant-biomarkers.com/#team
See also: Quant Biomarkers - Development and application of human biomarker panels and biological age metrics
Details last updated 14-Dec-2021
DKG subsidiary to introduce biomarker-driven Longevity risk mitigation and intervention support